PharmacoEconomics - Open

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
PharmacoEconomics - Open - Tập 3 - Trang 43-54 - 2018
D. Lee, A. Amadi, J. Sabater, J. Ellis, H. Johnson, S. Kotapati, S. McNamara, A. Walker, M. Cooper, K. Patterson, N. Roskell, Y. Meng
Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the Regimen in this population, with and without the availability of overall survival (OS) data. A partitioned survival model and a Markov state-transition model were developed to estimate the lif... hiện toàn bộ
Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
PharmacoEconomics - Open - Tập 6 Số 4 - Trang 629-629 - 2022
Fontrier, Anna-Maria, Visintin, Erica, Kanavos, Panos
Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
PharmacoEconomics - Open - Tập 1 - Trang 195-202 - 2017
Jörg Mahlich, Shinichiro Okamoto, Akiko Tsubota
Ibrutinib was introduced in Japan in 2016 as a new oral treatment option for patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). There is increasing interest from the Japanese government to assess economic aspects of new medical interventions, especially in the area of oncology. We describe the treatment patterns of Japanese patients with CLL, estimate the cost of the diseas... hiện toàn bộ
Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis
PharmacoEconomics - Open - Tập 6 - Trang 605-617 - 2022
Nafsika Afentou, Emma Frew, Samir Mehta, Natalie J. Ives, Rebecca L. Woolley, Elizabeth A. Brettell, Adam R. Khan, David V. Milford, Detlef Bockenhauer, Moin A. Saleem, Angela S. Hall, Ania Koziell, Heather Maxwell, Shivaram Hegde, Eric Finlay, Rodney D. Gilbert, Caroline Jones, Karl McKeever, Wendy Cook, Nicholas J. A. Webb, Martin T. Christian
Childhood steroid-sensitive nephrotic syndrome is a frequently relapsing disease with significant short- and long-term complications, leading to high healthcare costs and reduced quality of life for patients. The majority of relapses are triggered by upper respiratory tract infections (URTIs) and evidence shows that daily low-dose prednisolone at the time of infection may reduce the risk of relaps... hiện toàn bộ
Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study
PharmacoEconomics - Open - - 2021
Anees Ur Rehman, Mohamed Azmi Hassali, Sohail Ayaz Muhammad, Sadia Shakeel, Siew Chin Ong, Irfhan Ali Bin Hyder Ali, Jaya Muneswarao, Rabia Hussain
Can Private Provision of Primary Care Contribute to the Spread of Antibiotic Resistance? A Study of Antibiotic Prescription in Sweden
PharmacoEconomics - Open - Tập 5 - Trang 187-195 - 2020
David Granlund, Yana V. Zykova
Growing rates of antibiotic resistance, caused by increasing antibiotic use, pose a threat by making antibiotics less effective in treating infections. We aimed to study whether physicians working at privately and publicly owned health centres differed in the likelihood of prescribing antibiotics and choosing broad-spectrum over narrow-spectrum antibiotics. To estimate the effect of ownership on t... hiện toàn bộ
Value of Information Analysis: Are We There Yet?
PharmacoEconomics - Open - Tập 5 - Trang 139-141 - 2020
Haitham Tuffaha
Correction to: Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications
PharmacoEconomics - Open - Tập 5 - Trang 559-559 - 2021
Charles Ebuka Okafor
In the Key Points for Decision Makers, the second point, which previously read.
Identification and prioritisation of items for a draft participant-reported questionnaire to measure use of social care, informal care, aids and adaptations
PharmacoEconomics - Open - - 2024
Kirsty M. Garfield, Gail A. Thornton, Samantha Husbands, Ailsa Cameron, William Hollingworth, Sian M. Noble, Paul Roy, Joanna C. Thorn
Resource-use measurement is integral for assessing cost-effectiveness within trial-based economic evaluations. Methods for gathering resource-use data from participants are not well developed, with questionnaires typically produced for each trial and rarely validated. The healthcare module of a generic, modular resource-use measure, designed for collecting self-report resource-utilisation data, ha... hiện toàn bộ
Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
PharmacoEconomics - Open - Tập 1 Số 1 - Trang 13-23 - 2017
Jeff Richardson, Angelo Iezzi, Gang Chen, A S Maxwell
Tổng số: 308   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10